Drug target site within GP120 of HIV
AssigneeKflp Biotech, LLC
InventorsAndrey Vinnik, Peter Fedichev, Maxim Kholin, Christopher Molloy, Aron Katz
Life of this patent
Estimating the term…
Loading patent…
AssigneeKflp Biotech, LLC
InventorsAndrey Vinnik, Peter Fedichev, Maxim Kholin, Christopher Molloy, Aron Katz
Estimating the term…
The present invention relates to a method of designing an inhibitor of the binding of HIV (human immunodeficiency virus) glycoprotein (gp)120 to a CD4-receptor or to the integrin alpha4 beta7 (a4b7). The inhibitor interacts with at least two amino acid residues comprised in six motifs within the 3-dimensional structure of gp120. Also provided are compounds, pharmaceutical compositions thereof and uses thereof in the development of an inhibitor of the binding of a HIV gp120 to a CD4-receptor or an integrin alpha4 beta7 (a4b7). The inhibitors are useful for the prevention or treatment of an HIV infection and/or diseases associated with an HIV infection.
A method of generating a medicament for the treatment of HIV, comprising confirming that a known compound is an inhibitor of the binding of HIV (human immunodeficiency virus) glycoprotein (gp)120 to a CD4-receptor comprising the method of
A method of generating a medicament for the treatment of HIV, comprising confirming that a known compound is an inhibitor of the binding of HIV (human immunodeficiency virus) glycoprotein (gp)120 to a CD4-receptor comprising
Dependencies are inferred from the claim text.